Enzymotec (NASDAQ: ENZY) and Celanese (NYSE:CE) are both basic materials companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Enzymotec and Celanese’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Enzymotec $47.70 million 5.81 -$2.92 million ($0.27) -43.78
Celanese $5.39 billion 2.68 $900.00 million $5.82 18.30

Celanese has higher revenue and earnings than Enzymotec. Enzymotec is trading at a lower price-to-earnings ratio than Celanese, indicating that it is currently the more affordable of the two stocks.


Celanese pays an annual dividend of $1.84 per share and has a dividend yield of 1.7%. Enzymotec does not pay a dividend. Celanese pays out 31.6% of its earnings in the form of a dividend. Celanese has increased its dividend for 5 consecutive years.


This table compares Enzymotec and Celanese’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Enzymotec -12.32% -3.26% -2.99%
Celanese 13.66% 31.98% 11.39%

Insider & Institutional Ownership

15.9% of Enzymotec shares are owned by institutional investors. Comparatively, 96.2% of Celanese shares are owned by institutional investors. 0.4% of Celanese shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for Enzymotec and Celanese, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enzymotec 0 2 0 0 2.00
Celanese 1 4 9 1 2.67

Enzymotec currently has a consensus price target of $11.75, indicating a potential downside of 0.59%. Celanese has a consensus price target of $107.85, indicating a potential upside of 1.27%. Given Celanese’s stronger consensus rating and higher possible upside, analysts plainly believe Celanese is more favorable than Enzymotec.

Risk and Volatility

Enzymotec has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Celanese has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.


Celanese beats Enzymotec on 15 of the 17 factors compared between the two stocks.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor’s supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company’s clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.

Celanese Company Profile

Celanese Corporation (Celanese) is a technology and specialty materials company. The Company’s segments include Advanced Engineered Materials, Consumer Specialties, Industrial Specialties, Acetyl Intermediates and Other Activities. The Advanced Engineered Materials segment includes the Company’s engineered materials business and certain affiliates. The Consumer Specialties segment includes the Company’s cellulose derivatives and food ingredients businesses, which serve consumer-driven applications. The Industrial Specialties segment includes the Company’s emulsion polymers and ethylene vinyl acetate (EVA) polymers businesses. The Acetyl Intermediates segment includes the Company’s intermediate chemistry business, which produces and supplies acetyl products, including acetic acid, vinyl acetate monomer (VAM), acetic anhydride and acetate esters. The Company has operations in North America, Europe and Asia. As of December 31, 2016, the Company had 30 global production facilities.

Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.